| __timestamp | BioCryst Pharmaceuticals, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 179279000 |
| Thursday, January 1, 2015 | 1896000 | 186359000 |
| Friday, January 1, 2016 | 2699000 | 171785000 |
| Sunday, January 1, 2017 | 1702000 | 208136000 |
| Monday, January 1, 2018 | 471000 | 198405000 |
| Tuesday, January 1, 2019 | 4101000 | 224169000 |
| Wednesday, January 1, 2020 | 1676000 | 245044000 |
| Friday, January 1, 2021 | 7264000 | 252314000 |
| Saturday, January 1, 2022 | 6594000 | 268225000 |
| Sunday, January 1, 2023 | 4661000 | 304629000 |
| Monday, January 1, 2024 | 324203000 |
In pursuit of knowledge
In the competitive world of pharmaceuticals, cost efficiency is a critical factor for success. This analysis compares the cost of revenue efficiency between Taro Pharmaceutical Industries Ltd. and BioCryst Pharmaceuticals, Inc. from 2014 to 2023. Taro consistently outperformed BioCryst, with its cost of revenue peaking at approximately $324 million in 2024, a staggering 1,500% higher than BioCryst's highest recorded cost in 2021. Over the decade, Taro's cost of revenue grew by about 70%, reflecting its expanding operations and market reach. In contrast, BioCryst's costs fluctuated, with a notable increase of over 500% from 2014 to 2021, before stabilizing. This disparity highlights Taro's robust financial management and strategic growth, while BioCryst's variable costs suggest a more volatile operational environment. Missing data for BioCryst in 2024 indicates potential reporting gaps, emphasizing the need for comprehensive data analysis in financial assessments.
Eli Lilly and Company vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Pfizer Inc. vs BioCryst Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Amgen Inc. and Taro Pharmaceutical Industries Ltd.
Neurocrine Biosciences, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Catalent, Inc. and BioCryst Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Grifols, S.A. vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for ACADIA Pharmaceuticals Inc. and Taro Pharmaceutical Industries Ltd.
Cost of Revenue: Key Insights for MorphoSys AG and BioCryst Pharmaceuticals, Inc.
Analyzing Cost of Revenue: HUTCHMED (China) Limited and Taro Pharmaceutical Industries Ltd.
Cost of Revenue: Key Insights for Agios Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd. vs Galapagos NV: Efficiency in Cost of Revenue Explored
BioCryst Pharmaceuticals, Inc. vs Evotec SE: Efficiency in Cost of Revenue Explored